Impella支持的心源性休克患者院内心脏骤停:J-PVAD注册研究
该研究基于J-PVAD注册研究8577例接受Impella治疗的心源性休克患者,按心脏骤停表现分为院内心脏骤停(IHCA,n=1924)、无心脏骤停(n=4595)、院外心脏骤停(OHCA)伴自主循环恢复(ROSC,n=1321)及OHCA不伴ROSC(n=737)四组。主要终点为首次Impella启动后30天死亡率,IHCA组为48.1%,无心脏骤停组28.7%,OHCA伴ROSC组41.9%,OHCA不伴ROSC组62.5%(P<0.001)。与无心脏骤停相比,IHCA与更高死亡率独立相关(校正HR 1.54,95%CI 1.41-1.69,P<0.001),且大出血、Impella相关出血、肢体缺血、缺血性卒中及脓毒症发生率更高。IHCA组内,高龄、乳酸>4.0 mmol/L、肌酐>1.5 mg/dL、较长骤停时间及使用VA-ECMO与更高死亡率相关,而心肌炎和电除颤与更低死亡率相关。
要点
- Impella置入前IHCA患者30天死亡率为48.1%,显著高于无心脏骤停者的28.7%(P<0.001)。
- 与无心脏骤停相比,IHCA与30天死亡率独立相关(校正HR 1.54,95%CI 1.41-1.69,P<0.001)。
- IHCA组大出血、Impella相关出血、肢体缺血、缺血性卒中及脓毒症发生率均高于无心脏骤停组。
- IHCA组内,乳酸>4.0 mmol/L、肌酐>1.5 mg/dL、较长骤停时间及VA-ECMO使用与更高死亡率相关。
- IHCA组内,心肌炎和电除颤与更低死亡率相关;乳酸、肌酐和骤停时间呈非线性关联。
适用人群与场景
- J-PVAD注册研究中接受Impella治疗的心源性休克患者,共8577例,分为IHCA(n=1924)、无心脏骤停(n=4595)、OHCA伴ROSC(n=1321)、OHCA不伴ROSC(n=737)四组。
- IHCA亚组分析聚焦于Impella置入前发生院内心脏骤停的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:注册研究(J-PVAD)分析;样本量8577例,多中心(J-PVAD注册研究)。
- 人群:接受Impella治疗的心源性休克患者,分为IHCA(n=1924)、无心脏骤停(n=4595)、OHCA伴ROSC(n=1321)、OHCA不伴ROSC(n=737)。
- 主要终点:首次Impella启动后30天死亡率,IHCA组48.1%,无心脏骤停组28.7%,OHCA伴ROSC组41.9%,OHCA不伴ROSC组62.5%(P<0.001)。
- 与无心脏骤停相比,IHCA与更高死亡率相关(校正HR 1.54,95%CI 1.41-1.69,P<0.001),且大出血、Impella相关出血、肢体缺血、缺血性卒中及脓毒症发生率更高。
- IHCA组内,高龄、乳酸>4.0 mmol/L、肌酐>1.5 mg/dL、较长骤停时间及VA-ECMO使用与更高死亡率相关;心肌炎和电除颤与更低死亡率相关;乳酸、肌酐和骤停时间呈非线性关联。
证据类型、等级与局限
- 证据类型:注册研究分析(J-PVAD registry);证据等级或推荐强度原文未提及。
- 局限:原文未明确提及,但设计为注册研究,可能存在未测量混杂。
对床旁实践的改变
- 原文未提及
指南或共识出处
- J-PVAD注册研究;原文未提及具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Impella-treated cardiogenic shock (CS) includes distinct arrest presentations. In-hospital cardiac arrest (IHCA) during CS may reflect progressive in-hospital hemodynamic collapse, but outcomes after Impella support remain unclear.
AIMS: This study compared 30-day outcomes across four cardiac arrest presentations and identified mortality-associated factors among patients with IHCA before Impella implantation.
METHODS: Overall, 8577 J-PVAD patients with CS treated with Impella were classified as IHCA (n = 1924), no cardiac arrest (n = 4595), out-of-hospital cardiac arrest (OHCA) with return of spontaneous circulation (ROSC; n = 1321), or OHCA without ROSC (n = 737). The primary outcome was 30-day mortality from first Impella initiation. Multivariable Cox models and restricted cubic splines were used.
RESULTS: Thirty-day mortality was 48.1% in IHCA, 28.7% in no cardiac arrest, 41.9% in OHCA with ROSC, and 62.5% in OHCA without ROSC (P < 0.001). Compared with no cardiac arrest, IHCA was associated with higher mortality (adjusted HR, 1.54; 95% CI, 1.41-1.69; P < 0.001) and higher rates of major bleeding, Impella-related bleeding, limb ischemia, ischemic stroke, and sepsis. Within IHCA, older age, lactate >4.0 mmol/L, creatinine >1.5 mg/dL, longer arrest time, and venoarterial extracorporeal membrane oxygenation use were associated with higher mortality, whereas myocarditis and electrical defibrillation were associated with lower mortality. Spline analyses showed nonlinear associations for lactate, creatinine, and arrest time.
CONCLUSIONS: IHCA before Impella implantation identified a distinct, high-risk CS phenotype with high mortality and a substantial complication burden. Metabolic, renal, and low-flow injury may support early risk stratification and clinical decision-making.
参考来源
- Arai R, Kojima K, Fukamachi D, et al. In-hospital cardiac arrest in Impella-supported cardiogenic shock: insights from the J-PVAD registry. Resuscitation. 2026. PMID: 42727697. doi:10.1016/j.resuscitation.2026.111310
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。